{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:49:51Z","timestamp":1786985391392,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bja.2024.05.005","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:48:49Z","timestamp":1718815729000},"page":"260-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Charting the course for improved outcomes in chronic critical illness: therapeutic strategies for persistent inflammation, immunosuppression, and catabolism syndrome (PICS)"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0150-1950","authenticated-orcid":false,"given":"Valerie E.","family":"Polcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2379-1004","authenticated-orcid":false,"given":"Evan L.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-0140","authenticated-orcid":false,"given":"Shawn D.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Efron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4611-106X","authenticated-orcid":false,"given":"Jaimar C.","family":"Rincon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2024.05.005_bib1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/TA.0b013e318256e000","article-title":"Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care","volume":"72","author":"Gentile","year":"2012","journal-title":"J\u00a0Trauma Acute Care Surg"},{"key":"10.1016\/j.bja.2024.05.005_bib2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bja.2023.11.052","article-title":"Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities","volume":"132","author":"Chadda","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2024.05.005_bib3","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc10031","article-title":"Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis","volume":"15","author":"Bo","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.bja.2024.05.005_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.phrs.2016.07.019","article-title":"Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression","volume":"111","author":"Patil","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bja.2024.05.005_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13613-023-01109-w","article-title":"Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial","volume":"13","author":"Daix","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.bja.2024.05.005_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bja.2024.05.005_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","author":"Hotchkiss","year":"2019","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bja.2024.05.005_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s00134-019-05704-z","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab","volume":"45","author":"Hotchkiss","year":"2019","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.bja.2024.05.005_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bja.2024.05.005_bib10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bja.2024.05.005_bib11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group","volume":"25","author":"Opal","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.bja.2024.05.005_bib12","article-title":"Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial","volume":"3","author":"Leventogiannis","year":"2022","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.bja.2024.05.005_bib23","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.bja.2024.05.005_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bja.2024.05.005_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13054-019-2628-x","article-title":"Myeloid-derived suppressor cell function and epigenetic expression evolves over time after surgical sepsis","volume":"23","author":"Hollen","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.bja.2024.05.005_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cytogfr.2022.07.007","article-title":"MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets","volume":"69","author":"Zhang","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bja.2024.05.005_bib17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/MOG.0000000000000781","article-title":"Gut microbiota and sepsis: from pathogenesis to novel treatments","volume":"37","author":"Kullberg","year":"2021","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.bja.2024.05.005_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/TA.0000000000003803","article-title":"Multicompartmental traumatic injury and the microbiome: shift to a pathobiome","volume":"94","author":"Munley","year":"2023","journal-title":"J\u00a0Trauma Acute Care Surg"},{"key":"10.1016\/j.bja.2024.05.005_bib13","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3389\/fimmu.2019.01363","article-title":"Epigenetics in sepsis: understanding its role in endothelial dysfunction, immunosuppression, and potential therapeutics","volume":"10","author":"Cross","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bja.2024.05.005_bib20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.chest.2023.05.002","article-title":"Pediatric persistent inflammation, immunosuppression, and catabolism syndrome prevalence in sepsis-related mortalities: a 23-year institutional history","volume":"164","author":"Patterson","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.bja.2024.05.005_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/jhn.12798","article-title":"Persistent inflammation, immunosuppression and catabolism syndrome (PICS) in critically ill children is associated with clinical outcomes: a prospective longitudinal study","volume":"34","author":"Hauschild","year":"2021","journal-title":"J\u00a0Hum Nutr Diet"},{"key":"10.1016\/j.bja.2024.05.005_bib21","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1097\/PCC.0000000000003125","article-title":"Defining pediatric chronic critical illness: a scoping review","volume":"24","author":"Zorko","year":"2023","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.bja.2024.05.005_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1542\/hpeds.2016-0107","article-title":"Defining pediatric chronic critical illness for clinical care, research, and policy","volume":"7","author":"Shapiro","year":"2017","journal-title":"Hosp Pediatr"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091224002733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091224002733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:54:01Z","timestamp":1754009641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091224002733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0007091224002733"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2024.05.005","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Charting the course for improved outcomes in chronic critical illness: therapeutic strategies for persistent inflammation, immunosuppression, and catabolism syndrome (PICS)","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2024.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2023.11.052","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 British Journal of Anaesthesia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}